RGLS (Regulus Therapeutics) Tax Provision : $-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Tax Provision?

Regulus Therapeutics's tax provision for the three months ended in Dec. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.00 Mil.

Regulus Therapeutics Tax Provision Historical Data

The historical data trend for Regulus Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Tax Provision Chart

Regulus Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

Regulus Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Regulus Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Regulus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

7RG0:Germany

Address

4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121

Website

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Executives

David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Joseph P Hagan	officer: Chief Operating Officer	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Ray Aker	officer: Sr. VP & General Counsel	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Crispina Calsada	officer: Chief Financial Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Preston Klassen	officer: President & Head of R & D	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kathryn J Collier	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Denis Drygin	officer: Chief Scientific Officer	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang	director	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Growth Equity Opportunities V, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Scott D Sandell	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025